We have offered the news, the move, and color on each where applicable.

BP plc (NYSE: BP) is trading lower again.  Reports are out that a single bill was sent in from the White House for over $51 million.  The problem is that the BP ADRs are trading under $30.00 this morning.  Shares are down over 3% at $29.25 in active trading.  Keep in mind that the prior 52-week low is $29.00.

Dell Inc. (NASDAQ: DELL) is considering going private, according to MarketWatch. But the problem is that there is nothing new here.  Michael Dell already threw that notion out before.  Shares are down 1% on thin volume at $13.80.

EnteroMedics, Inc. (NASDAQ: ETRM) announced updated data from its EMPOWER study showing that it saw significant sustained improvements in glycemic control and blood pressure.  Shares are up by 30% at $0.38 on about 25,000 shares.  With a $13 million market cap, this one can go either way.  The 52-week range is $0.27 to $5.58.

Evergreen Solar Inc. (NASDAQ: ESLR) signed an agreement with Praxair China to supply bulk industrial gases.  Shares are up 2.5% at $0.88 but these supply pacts often end up fading when terms are not set.

Extreme Networks, Inc. (NASDAQ: EXTR) is trading up after it was selected by the Austrian Ministry of the Interior for data center and local networks addressing national security.  There have only been about 7,000 shares traded but shares are up 7% at $3.06 this morning versus a 52-week range of $1.65 to $3.79.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) is trading up this morning after it received a third extension of its debt-holder waiver agreement.  Shares are up 13% at $2.04 as it gets to continue restructuring plans.

SonicWALL Inc. (NASDAQ: SNWL) is up on word that it is being sued by holders for selling itself to cheaply.  Shares were up 5% earlier and the stock is now trading up 4.7% at $11.89 on more than 2 million shares.

Uranium Resources, Inc. (NASDAQ: URRE) is trading lower after pricing a public secondary offering of 23,809,500 shares at $0.42 per share. Shares closed at $0.52 yesterday and the stock is trading down 15.5% at $0.44.  With shares close to 300,000 already, it has passed an average day’s volume.

Walgreen Company (NYSE: WAG) is lower after the drugstore giant reported earnings at $0.53 EPS, shy of Thomson Reuters figures by $0.04. Revenues were up 6% to $17.2 billion, above the $17.1 billion estimate.  Shares are down 2.5% at $29.38 on about 150,000 shares and the 52-week range is $27.89 to $40.69.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Amgen Inc. (NASDAQ: AMGN) is hardly budging on any follow-through trading, despite the news that the company has said it wants to be on the acquisition path.  We have addressed some of the issues behind M&A here.

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is surging on news that Roche’s diabetes drug faces an FDA delay of what looks to be 12 to 18 months.  Shares were up ‘only’ 12% pre-market and now the stock is up a sharp 18% at $19.53 on more than 11 million shares.

Alkermes Inc. (NASDAQ: ALKS) is up after the FDA notified it of the tentative scheduling of a FDA advisory committee meeting set for September 16 for review of its supplemental new drug application for Vivitrol, an alcohol-dependency treatment it also wants to use as an aid against opioid addiction.
Shares are up 9.4% at $12.65 on 2.2 million shares.

Dendreon Corp. (NASDAQ: DNDN) is hardly lower on some prostate cancer competition after the FDA approved Jevtana from Sanofi-Aventis (NYSE: SNY).  After looking and considering things, there is reason to believe this is almost no financial competition at all.

Genzyme Corporation (NASDAQ: GENZ) is higher today on its an accelerated share buyback plan of $1 billion as part of a $2 billion buyback plan.  It is worth wondering if Genzyme is wasting its capital buying back stock over other alternatives.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) has been touted and is surging by 19% to $1.94 on only about 1.6 million shares.  The 52-week range is $1.05 to $7.75 and it trades about 600,000 shares a day.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Array BioPharma, Inc. (NASDAQ: ARRY) is the biggest winner so far on a $467 million drug pact that was an alternative to a merger.  Shares have held up rather well and the stock is up 35% at $4.09 on almost 16 million shares.  Shares hit $4.25 today and the 52-week high is $4.65.

BioDelivery Services International Inc. (NASDAQ: BDSI) is one of the worst performers in the BioHealth space due to its raising $10 million in a registered direct offering from institutional investors.  Shares are down over 14% at $3.61 on over 2 million shares of stock.  The market cap is a mere $76 million and the average volume here is only about 90,000 shares.

Biogen Idec Inc. (NASDAQ: BIIB) is one of the few situations where a Carl Icahn movement needs to actually work out.  The stock is down today, but just marginally, after the TYSABRI drug maker for MS said its profit fell on charges despite Tysabri sales having risen.  Shares are down 1.9% at $53.74 and we have not quite yet seen the 2.6 million shares hit on an average day.

Biosante Pharmaceuticals, Inc. (NASDAQ: BPAX) is trading up again today.  Yesterday’s news was that it will present and separately participate in a cancer immunotherapy panel discussion at the World Vaccine Congress.  Shares are up 5.8% at $2.00 on what is already triple volume after 1.8+ million shares have traded hands.

CytRx Corporation (NASDAQ: CYTR) is up after its Bafetinib received a positive opinion from the Committee for Orphan Medicinal Products in the European Union indication for treatment of chronic myeloid leukemia or CML.  Shares are up 9.7% at $1.13 on over 6 million shares mid-afternoon, which is already about 8-times normal volume if they closed the market now. Its market cap is $123 million and the 52-week trading range is $0.35 to $1.72.

Human Genome Sciences, Inc. (NASDAQ: HGSI) is in trouble, and frankly it is lucky the fallout is not worse.  The company’s GlaxoSmithKline-partner study of topline 76-week results of its Phase III trial of Benlysta in Systemic Lupus Erythematosus actually failed to meet a secondary endpoint.  The primary endpoint is still met, but this is a disappointment.  Shares are down 6% at $29.60 on more than 22 million shares.  The 52-week range is $1.16 to $34.49 and the average volume is a more 3.1 million shares.

Neuralstem, Inc. (AMEX: CUR) is up on what may be no fixed news other than outside commentary.  Shares are up over 20% at $2.75 and the trading volume is very high with well over 2 million shares having traded hands.

Prana Biotechnology Ltd. (NASDAQ: PRAN) played more profit taking after yesterday’s large run up followed by profit taking.  Shares closed up 78% at $2.41 yesterday but had been as high as $3.35 after showing some Alzheimer’s Disease effects reversed in some study presentations.  The stock is down another 15% at $2.05 today on over 2.3 million shares.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Acura Pharmaceuticals Inc. (NASDAQ: ACUR) is higher before Thursday’s FDA advisory panel is set to discuss the drug company’s lead candidate, called Acurox, which is for pain relief.  Shares are up 45% at $8.50 on over 1.4 million shares.  The market is listed now as $369 million.

Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) is surprisingly soft and quiet considering that this morning was its earnings, and its losses narrowed on narrower expenses.  Shares are down 2.3% at $21.24 on 2.7 million shares, which is barely 60% of a full day’s trading volume.

Biogen Idec Inc. (NASDAQ: BIIB) is up, while Elan Corp. plc (NYSE: ELN) is down after Elan said it is considering spinning off its drug delivery operations.  Elan is down 2.8% at $7.50 and Biogen Idec is up 2.1% at $54.78.

Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) is rising after the company released data that it plans to resubmit its new drug application for OFIRMEV pain shot.  The stock is up 14% at $10.48 on 1.2 million shares (over 3-times normal volume).

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) looks to be up on block volume besides chat room discussions.  Shares are up 4.9% at $2.78 on over 11 million shares of stock, which is so far the most volume since Feb. 17 when it traded 13.8 million shares.

Human Genome Sciences, Inc. (NASDAQ: HGSI) is down after its partner Novartis withdrew its European Medicines Agency application for approval of JOULFERON for the treatment of chronic hepatitis C.  Shares are down 3% at $31.43 on over 3.4 million shares.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) is running higher in recovery after debt discussions last week after shares fell each day after an almost 200% gain on Tuesday.  Shares are up 13.7% at $2.57 on 1 million shares.  This is more evidence of continued trader interest back and forth more than breaking news or breaking rumors.

Prana Biotechnology Ltd. (NASDAQ: PRAN) is acting like the next ten-bagger chase after positive Alzheimer’s data, the difference being that is over reversal of the effects rather than delay of effects.  Shares were up over 100% earlier before coming off highs.

Rexahn Pharmaceuticals, Inc. (AMEX: RNN) is down today after last week’s gains.  This may be profit taking, but TheStreet.com says there are “holes galore in Serdaxin data.”  Shares are down 15% at $2.41 on almost 5 million shares.

Sequenom Inc. (NASDAQ: SQNM) is up after its launch of the new MassARRAY Analyzer 4, with the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications.  Shares are up 3.6% at $6.01 on over 8.3 million shares.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

We have provided news updates, added color where applicable, shown the price moves with volume and comparative data on each.

AEterna Zentaris (NASDAQ: AEZS) may be hard to pronounce, but shares are up after it said the European Medicines Agency assured the acceptability of its Phase III programs for its lead anti-cancer drug, perifosine.  This is for the treatment of multiple myeloma and refractory advanced colorectal cancer.  Shares are up 15% at $1.59 on well over 9 million shares; average volume is only about 750K and the 52-week range is $0.75 to $3.25.

Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) is up after showing 72% of patients receiving ANA598 in a phase II combination study with interferon and Ribavirin achieved undetectable levels of virus at week eight.  Shares are up 8.6% at $2.84, but shares had been up as high as $3.24 today.  Mid-day volume is 11 million shares versus only about 500K on average, and the 52-week range is $1.44 to $6.45.

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is down 8.5% at $2.98, but shares had been as high as $3.20 and the 52-week range is $1.10 to $3.89.  The news is that the company is presenting data from studies of ACH-1625 in Hepatitis C at the EASL International Liver Congress that shows a significant reduction in HCV RNA.

Akorn Inc. (NASDAQ: AKRX) is up after it received FDA clearance to market a generic version of the painkiller Dilaudid-HP, and it plans to start shipping the product next month.   Shares are up over 15% at $1.64 on about 1.7 million shares.  The 52-week range is $0.73 to $2.00 and the average volume is only about 206,000 shares.

Dynavax Technologies Corporation (NASDAQ: DVAX) is up oh hepatitis news as well, after it showed that its chronic kidney disease study confirms that HEPLISAV offers  enhanced seroprotection against HBV infection.  Shares had been up over 16% earlier on the news.  In early-afternoon trading the stock is up over 8% at $1.57 on 3.9 million shares (over 10-times normal volume).

Genzyme Corp. (NASDAQ: GENZ) is fighting Carl Icahn via another activist…. Genzyme and Relational Investors LLC have amended their mutual cooperation agreement and Ralph Whitworth, principal and co-founder of Relational, has been elected to Genzyme’s board of directors, effective immediately, and he will chair a new Strategic Planning and Capital Allocation Committee.  Genzyme is up a mere 0.25% at $52.79.

Idenix Pharmaceuticals Inc. (NASDAQ: IDIX) is also up on hepatitis news after it reported positive results on its IDX184 in interim analysis of a Phase IIa hepatitis C study.  The shares were up over 16% earlier today, but the stock is up 8.6% at $4.43 on 1.5 million shares now.

Molecular Insight Pharmaceuticals (NASDAQ: MIPI) has another give-back after a large move up this week.  Today’s drop is after the stock was downgraded to “Market Perform from Outperform” at Wells Fargo.  Shares are down 7% more at $2.67, but only on about 700,000 shares.  Keep in mind that ‘my-pie’ was only at $1.50 on Monday and traded as high as $4.49 on Tuesday.

Repros Therapeutics Inc. (NASDAQ: RPRX) is down today on exchange related news.  It said it now has enough stockholders’ equity for NASDAQ compliance, and it has until June 14, 2010 to meet the NASDAQ minimum $1.00 rule.  Shares are down 7.8% at $0.73 on just over 1.5 million shares.

Santarus Inc. (NASDAQ: SNTS) was down in half last night after the U.S. District Court for the District of Delaware ruled that five patents covering ZEGERID® prescription products are invalid due to obviousness (indicated for the treatment of certain upper GI diseases and disorders).  Shares are down 32% at $3.64 on over 10 million shares.

Warner Chilcott PLC (NASDAQ: WCRX) may still be on the way to being the next best drug stock out there.  Shares were up on positive UBS comments yesterday and IBD said its chart was #66 but third best in class today.  Shares were up another 3.2% at $27.69 and the highest level since March 8, 2010.

JON C. OGG

American Superconductor Corporation (NASDAQ: AMSC) Raised to Buy at Deutsche Bank.
GT Solar International, Inc. (NASDAQ: SOLR) Started as Buy at Wunderlich.
Marathon Oil Corporation (NYSE: MRO) Started as Outperform at Credit Suisse.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) Cut to Market Perform at Wells Fargo.
Sunoco Inc. (NYSE: SUN) Started as Outperform at Credit Suisse.
Tesoro Corporation (NYSE: TSO) Started as Neutral at Credit Suisse.
Tiffany & Co. (NYSE: TIF) Started as Buy at Deutsche Bank.
United Parcel Service (NYSE: UPS) Raised to Overweight at Piper Jaffray.
Valero Energy Corp. (NYSE: VLO) Started as Outperform at Credit Suisse.
Zions Bancorp (NASDAQ: ZION) Raised to Buy at SunTrust Robinson Humphrey.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON OGG

We have included the news summaries, price reactions, and have given some added color on each where applicable.

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) is trading up and recovering some of its losses from the peak of the last year after it announced that Dr. Friedman will present additional data demonstrating that pimavanserin was safe and well tolerated for Parkinson’s Disease psychosis at the 62nd American Academy of Neurology Annual Meeting.  Shares are up 7.4% at $1.89 on 2.4 million shares.  Average volume is only 582,000 shares and the 52-week range is $0.88 to $6.60. UPDATE FOR CLOSE: shares closed at $1.77, up only 0.57% on over 3.9 million shares.

Adeona Pharmaceuticals, Inc. (AMEX: AEN) is considerably higher after it announced positive results of part 1 of its CopperProof-2 study in Alzheimer’s Disease patients and noted mild cognitive impairment.  Shares have a new 52-week high of $2.70, and the stock is up a sharp 41% at $2.15.  Even after today’s gains it has a mere $46.6 million market cap. UPDATE FOR CLOSE: shares closed up 24.3% at $1.89 on 10.7 million shares.

CombinatoRx, Incorporated (NASDAQ: CRXX) is up after it announced the discovery of a novel multi-target mechanism to treat hematologic malignancies.  Shares are up 6% at $1.41 on 3.2 million shares.  The average volume is 2.5 million shares and the 52-week trading range is $0.49 to $2.60. UPDATE FOR CLOSE: shares closed at $1.38, up 3.76% on 4.8 million shares.

Dendreon Corporation (NASDAQ: DNDN) has managed to recover and is in positive territory after the stock downgraded by Citigroup on valuation and the target is $40.00.  Shares are up 0.26% at $38.93 and the stock has traded as low as $38.17 early this morning. UPDATE FOR CLOSE: shares closed at $39.12, up 0.75% on 3.73 million shares.

Exact Sciences Corp. (NASDAQ: EXAS) sold 4,200,000 shares of common stock at a price of $4.50 per share in a public secondary offering to receive net proceeds of about $17.6 million after fees. The funds are going to the company and it is still seeking to obtain FDA clearance of its sDNA colorectal cancer screening product.  Shares closed at $4.69 yesterday and the stock is down 3.4% at $4.53 on over 400,000 shares.  The average volume is only 173,000 shares per day and this was at $4.85 5 trading days ago. UPDATE FOR CLOSE: shares closed at $4.53, down 3.4% at $4.53.

InterMune, Inc. (NASDAQ: ITMN) is hardly reacting to what looked like positive news.  The company reported that its top-line results from a Phase IIb study of Danoprevir in patients with chronic Hepatitis C were among the very best reported by any DAA compound to date.  The news sounded big but the stock reaction is muted…. up 0.67% at $48.25 on only 600,000 shares.  The 52-week range is $10.48 to $49.05, so there has already been much movement ahead of the news.  Average volume is 2.4 million shares.  UPDATE FOR CLOSE: shares closed at $48.14, up 0.44% on only 1.3 million shares.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) was the biggest winner of all on Tuesday with a gain of  over 100% as we had noted as a “chasing 10-baggers” example of biotech investors running up stocks on positive cancer news.  Shares are giving back a sharp 20% at $2.76 on continued profit taking and a rethinking of the huge move.  Two days ago this was a $1.50 stock, yet yesterday’s high was an amazing $4.49 and the 52-week range is $1.05 to $7.90.  UPDATE AT CLOSE: My-pie closed down 16% at $2.88 on 3.1 million shares.

Orexigen Therapeutics, Inc. (NASDAQ: OREX) is recovering again from the lows today after shares dropped from over $5.80 to under $5.00 before stabilizing yesterday on news that it was revising data on its obesity drug.  Today’s gain so far is up 3.9% at $5.30 on about 450,000 shares versus and average volume of about 550,000 shares. UPDATE FOR CLOSE: shares closed at $5.51, up 4% on 1.29 million shares.

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) has announced that its formal earnings report will be released on April 22, 2010 after the markets closes.  This alone does not matter, but the pending Astellas hostile tender offer is April 23, 2010.  As noted last week, some trades and bets are being made that the premium above the $52.00 will not be justified in today’s prices.  UPDATE FOR CLOSE: shares closed at $60.00, up 0.4% on only 718,000 shares.

Rexahn Pharmaceuticals, Inc. (AMEX: RNN) is trading up after it issued additional comments and some clarifications on its phase IIa study results of serdaxin in major depressive disorder.  Shares are up over 10% at $1.95 on 8.77 million shares.  The 52 week range is $0.40 to $3.68 and the average volume is just under 2 million shares. UPDATE FOR CLOSE: shares closed up 22% at $2.15 on almost 15.3 million shares.

Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) is trading higher on analyst coverage as the stock was initiated with an ‘Overweight’ rating by Thomas Weisel.  Shares are up 2.25% at $40.00 and the $40.03 high today marks a 52-week high with the new range of the last 52-weeks being $8.78 to $40.03. UPDATE FOR CLOSE: shares closed at $39.64, up 1.3% on 1.11 million shares.

VIVUS Inc. (NASDAQ: VVUS) is seeing a very muted reaction to an analyst research call.  Its shares were initiated with a BUY rating at Needham with a $15.00 price target.  Shares are up a mere 0.8% at $8.94 on 2.1 million shares already in under two hours of trading; the average volume is only 2.4 million shares and the 52-week range is $3.61 to $12.88.  UPDATE FOR CLOSE: shares closed up 2.8% at $9.12 on 4.2 million shares.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

Ambac Financial Group Inc. (NYSE: ABK) is up big again on continuation of the same news from last Thursday after 50%+ gains Friday and 100%+ gains on Monday.

Palm, Inc. (NASDAQ: PALM) was down over 3% and is getting worse as some reality is coming into play over what it may fetch in a buyout.

EntreMed, Inc. (NASDAQ: ENMD) is up over 25% on cancer news this morning.

Xoma Ltd. (NASDAQ: XOMA) is surging 20% on patent awards.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) is looking to b today’s easy winner as shares are up nearly 200% on positive cancer news.

Popular, Inc. (NASDAQ: BPOP) is up double-digits despite a securities offering and a loss.

Goldman Sachs did an analyst coverage switcheroo and shares of Expedia Inc. (NASDAQ: EXPE) are up while Priceline.com Inc. (NASDAQ: PCLN).

Huntington Bancshares Inc. (NASDAQ: HBAN), KeyCorp. (NYSE: KEY), and Regions Financial Corp. (NYSE: RF) are all lower by 2% to 3% after UBS cut their ratings down to a SELL rating.

You can join our free daily email distribution list to hear more about dividend trends, analyst upgrades and downgrades, top day trader and active trader alerts, news on Buffett and other investment gurus, IPOs, secondary offerings, private equity, and more.

JON C. OGG

We have included the moves as they have been seen in late-morning trading as well the news and a link to more data on each were applicable if these were more broad stories.

Abraxis BioScience, Inc. (NASDAQ: ABII) is scoring a win in the war against lung cancer.  Its ABRAXANE showed high promise in combination with existing treatments for lung cancer in key Phase III  studies.  In late-morning trade, Abraxis is up over 28% at $21.18 and it hit a high of $54.03 today.  We have already seen 5-times normal volume.

StemCells Inc. (NASDAQ: STEM) is up on news of a rat model patent award in the UK.  This is apparently a novel stem cell patent despite the animal model.  Shares are up 2.5% at $1.24 and we have already seen almost 2 million shares trade versus a 2.1 million share average day.

Xenoport, Inc. (NASDAQ: XNPT) is up 4.5% at $9.57 on no real news seen.  Xenoport is the one that was clocked last month after failing to win FDA support of its restless leg syndrome and after half of its workforce was forced into national employee morale day for layoffs.  Still, if news is out we haven’t seen it today.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) took a beating of almost 10% to close at $1.28 yesterday due to its large securities offering.  Shares have recouped over 2% of that today and the stock is at $1.31 on already 150% of normal trading volume.

• Barrier Therapeutics (NASDAQ: BTRX) ran way up after first quarter results reported yesterday showed a 207% increase in revenues from last year at $8.4 million, driven by growth in sales of Vusion and Xolegel. Shares closed up 18% at $2.29 on a 52-week range of $1.90 to $7.60.
• BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) showed a first quarter positive profit or $0.02 EPS on a net income of $1.7 million. Analysts expected losses of $0.05 EPS. Earnings were driven primarily by sales of enzyme replacement therapy Naglazyme. Shares closed up almost 8% at $36.46. The 52-week range is $15.99 to $41.00.
• Discovery Labs (NASDAQ: DSCO) trading up in anticipation of FDA approval for lung surfactant, Surfaxin, a treatment for premature infants suffering from respiratory distress. The company communicated confidence that any regulatory concerns have been ironed out and this third FDA result will be positive. Shares rose 17% to $2.87. The 52-week range is $1.75 to $3.75.
• Endo Pharmaceuticals (NASDAQ: ENDP) settled a proxy battle with shareholder D.E. Shaw by nominating William Spangler to the board. They posted earnings today showing a net income of $59.53 and $0.44 EPS. Shares closed down 0.7% at $24.83. The 52-week range is $22.62 to $35.85.
• Mannkind Corporation (NASDAQ: MNKD) up over 16% in anticipation of earnings release Monday. Shares up $0.37 at $2.60 at the close. The 52-week range is $1.86 to $14.71.
• Molecular Insight Pharma (NASDAQ: MIPI) up almost 7% today on no news, although some just may be the thin volume and wide bid/ask spread. The oncology molecular imaging pharmaceutical company is sitting at $7.83 on a 52-week range of $5.66 to $12.95.
• Questcor (AMEX: QSC) down despite posting strong first quarter results showing a positive net income of $6.5 million compared to a loss of $3.8 in first quarter 2007. The company also amended agreement Acthar distribution discount prices, positively impacting Questcor cash flows. Shares closed down 2.5% at $4.24. The 52-week range is $0.21 to $6.60.
• Techne Corp. (NASDAQ: TECH) up after third quarter profit jumped 24% to $29.6 million or $0.76 EPS, beating estimates. Shares closed at $72.52, up 1%, on a 52-week range of $54.49 to $72.00.

Rachel Lopez
April 30, 2008